Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 332 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors March 27, 2025 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... May 9, 2022 Load more HOT NEWS Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... Her Massive Weight Loss Helped Her Feel A Lump In Her... Five Questions With…Keon. FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma
